Newsfeeds Archive - Page 6682 of 19074

1 minute read

Purple Biotech To Present New CM24 Pancreatic Cancer Biomarker Data At AACR Special Conference On September 28, 2023

September 21, 8:21 AM

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune

PPBT

3 minute read

CGT Global And Octomera Enter Agreement To Expand Cell & Gene Therapy Development And Patient Access Across The United States

By Benzinga Newsdesk

September 21, 8:20 AM

Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the Point of Care (POCare) network and

ORGS

1 minute read

News

Allstate Announces August 2023 Catastrophe Losses And Implemented Rates; Losses For The Month Of August Of $551M Or $435M, After-Tax

By Benzinga Newsdesk

September 21, 8:19 AM

The Allstate Corporation (NYSE:ALL) today announced estimated catastrophe losses for the month of August of $551 million or $435 million, after-tax.August month catastrophe losses include 18 events estimated at $641

ALL

1 minute read

What’s Going On With Alibaba Stock Thursday?

By Anusuya Lahiri

September 21, 8:18 AM

Alibaba Group Holding Limited (NYSE: BABA) stock is trading lower Thursday in line with the broader indexes IShares MSCI China ETF (NASDAQ:

BABA

2 minute read

News

Wearable Devices To Enhance Apple Watch Series 9 New ‘DoubleTap’ Feature With Its Mudra Band Touchless Gesture Control

By Benzinga Newsdesk

September 21, 8:10 AM

Using the Mudra Band spatial gestures in tandem with the Apple Watch Double Tap gesture should allow for full touchless control across the Apple product ecosystemYOKNEAM ILLIT, ISRAEL, Sept. 21, 2023 (GLOBE NEWSWIRE) --

AAPL

2 minute read

89bio Announces U.S. FDA Has Granted Breakthrough Therapy Designation For Pegozafermin In Nonalcoholic Steatohepatitis

By Benzinga Newsdesk

September 21, 8:09 AM

–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the fourth quarter of

ETNB

2 minute read

Silicon Motion Provides Certain Details Regarding MaxLinear’s Surprise Termination Of The Merger Agreement

By Benzinga Newsdesk

September 21, 8:09 AM

Silicon Motion Technology Corporation (NASDAQ:SIMO) ("Silicon Motion" or "the Company") today disclosed additional details regarding MaxLinear's termination of its May 5, 2022 agreement to acquire the Company (the

MXL

2 minute read

CymaBay Initiates AFFIRM, A Phase 3b/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis

By Benzinga Newsdesk

September 21, 8:08 AM

AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar's accelerated

CBAY

3 minute read

Daré Bioscience Announces Grant Funding Installment To Support Further Development Of Novel Contraceptive Technology DARE-LARC1; Daré May Receive A Total Of Up To Approximately $49 Million To Support Nonclinical Development Of DARE-LARC1

By Benzinga Newsdesk

September 21, 8:06 AM

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the

DARE

2 minute read

Tyra Biosciences Announces Oral Presentations On TYRA-300 For Achondroplasia At The ASBMR And ASHG 2023 Annual Meetings

By Benzinga Newsdesk

September 21, 8:05 AM

Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR)

TYRA